| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmaceutics, University of Washington, Seattle, Washington 98195 [S. R., J-S. Y., T. F. K., J. T. S.]; the Korea Food and Drug Administration, Seoul 122-020, Korea [J-S. Y.]; and the Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024 [J. T. S.]
We have investigated the formation of 4-hydroxycyclophosphamide (HCY) and deschloroethylcyclophosphamide (DCCY) from cyclophosphamide (CY) in human liver microsomes. For HCY, the estimated values (mean ± SD; n = 3) of Km1 and Km2 were 0.095 ± 0.072 and 5.09 ± 4.30 mM, and the estimated values of Vmax1 and Vmax2 were 0.138 ± 0.070 and 1.55 ± 0.50 nmol/min/mg protein. For DCCY, Km1 and Km2 were 0.046 ± 0.017 and 8.58 ± 5.84 mM, and Vmax1 and Vmax2 were 0.006 ± 0.003 and 0.274 ± 0.214 nmol/min/mg protein. At Cy concentrations of 0.1, 0.7, and 5 mM, HCY respectively accounted for 95.7 ± 1.3, 95.1 ± 2.4, and 90.7 ± 2.7% of the total products of CY (HCY + DCCY; n = 6). In a separate experiment, 98.7 ± 11.9% (n = 3) of CY loss could be accounted for by the formation of HCY at 0.1 mM CY. On the basis of cytochrome P450 (CYP) isoform-specific chemical inhibitor and cDNA-expressed human P450 isozyme studies, CYP2C9 and CYP3A4/5 seemed to be the major P450 isoforms responsible for HCY formation at low (0.1 mM) and high (0.7 and 5 mM) concentrations of CY, respectively. Although orphenadrine inhibition was observed in human liver microsomes (which has been taken to indicate CYP2B6 catalysis), orphenadrine inhibited cDNA-expressed CYP3A4 formation of HCY to the same extent observed in human liver microsomes, and the addition of orphenadrine to incubations containing sulfaphenazole (a specific inhibitor of CYP2C9) or troleandomycin (a specific CYP3A inhibitor) did not increase inhibition beyond that observed with sulfaphenazole or troleandomycin alone. Similar studies indicated that CYP3A4/5 was the major P450 isoform responsible for DCCY formation at high (0.7 and 5 mM) concentrations of CY. The P450 isoform responsible for DCCY formation at 0.1 mM CY could not be identified due to its very low formation rate.
1 Supported in part by NIH Grants CA 18029 and GM 32165.
2 To whom requests for reprints should be addressed, at Fred Hutchinson Cancer Research Center, AB-122, 1100 Fairview Ave. N, P.O. Box 19024, Seattle, WA 98109-1024. Phone: (206) 667-3372; Fax: (206) 667-6115; E-mail: jts@u.washington.edu.
Received 3/ 4/97. Accepted 7/28/97.
This article has been cited by other articles:
|
|
 |
|
  P. Afsharian, Y. Terelius, Z. Hassan, C. Nilsson, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats Clin. Cancer Res., July 15, 2007; 13(14): 4218 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Salinger, J. S. McCune, A. G. Ren, D. D. Shen, J. T. Slattery, B. Phillips, G. B. McDonald, and P. Vicini Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach. Clin. Cancer Res., August 15, 2006; 12(16): 4888 - 4898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Petros, P. J. Hopkins, S. Spruill, G. Broadwater, J. J. Vredenburgh, O. M. Colvin, W. P. Peters, R. B. Jones, J. Hall, and J. R. Marks Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6117 - 6125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Walsh, P.W. Hastwell, P.O. Keenan, A.W. Knight, N. Billinton, and R.M. Walmsley Genetic modification and variations in solvent increase the sensitivity of the yeast RAD54-GFP genotoxicity assay Mutagenesis, September 1, 2005; 20(5): 317 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al. Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Qiu, T. F. Kalhorn, and J. T. Slattery ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1204 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Yule, L. Price, A. D. McMahon, A. D. J. Pearson, and A. V. Boddy Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma Clin. Cancer Res., January 15, 2004; 10(2): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. McDonald, J. T. Slattery, M. E. Bouvier, S. Ren, A. L. Batchelder, T. F. Kalhorn, H. G. Schoch, C. Anasetti, and T. Gooley Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood, March 1, 2003; 101(5): 2043 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lindley, G. Hamilton, J. S. McCune, S. Faucette, S. S. Shord, R. L. Hawke, H. Wang, D. Gilbert, S. Jolley, B. Yan, et al. The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes Drug Metab. Dispos., July 1, 2002; 30(7): 814 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yao, S. Ding, B. Burchell, C. R. Wolf, and T. Friedberg Detoxication of Vinca Alkaloids by Human P450 CYP3A4-Mediated Metabolism: Implications for the Development of Drug Resistance J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 387 - 395. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Wandel, R. B. Kim, S. Kajiji, F. P. Guengerich, G. R. Wilkinson, and A. J. J. Wood P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies Cancer Res., August 1, 1999; 59(16): 3944 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Roy, L. J. Yu, C. L. Crespi, and D. J. Waxman Development of a Substrate-Activity Based Approach To Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles Drug Metab. Dispos., June 1, 1999; 27(6): 655 - 666. [Abstract] [Full Text]
|
|
|
|
|
|
C. P. Granvil, A. Madan, M. Sharkawi, A. Parkinson, and I. W. Wainer Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of (R)- and (S)-Ifosfamide in Human Liver Microsomes Drug Metab. Dispos., April 1, 1999; 27(4): 533 - 541. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Yule, D. Walker, M. Cole, L. McSorley, S. Cholerton, A. K. Daly, A.D.J. Pearson, and A. V. Boddy The Effect of Fluconazole on Cyclophosphamide Metabolism in Children Drug Metab. Dispos., March 1, 1999; 27(3): 417 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. Yu, P. Drewes, K. Gustafsson, E. G. C. Brain, J. E. D. Hecht, and D. J. Waxman In Vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 928 - 937. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ren, T. F. Kalhorn, and J. T. Slattery Inhibition of Human Aldehyde Dehydrogenase 1 by the 4-Hydroxycyclophosphamide Degradation Product Acrolein Drug Metab. Dispos., January 1, 1999; 27(1): 133 - 137. [Abstract] [Full Text]
|
|
|
|
|
|
R. De Salvia, M. Fiore, T. Aglitti, F. Festa, R. Ricordy, and R. Cozzi Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage Mutagenesis, January 1, 1999; 14(1): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
